Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Goh

Showing results (381-390 of 391) with videos related to

Pageof 40
Sort By:
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J Motzer, Camillo Porta, Masatoshi Eto, et al.
Radiology|April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerNarjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The New England Journal of Medicine|February 22, 2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Boris Alekseev, Sun-Young Rha, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 40

Showing results (381-390 of 391) with videos related to

Sort By:
Pageof 40
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J Motzer, Camillo Porta, Masatoshi Eto, et al.
Radiology|April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerNarjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The New England Journal of Medicine|February 22, 2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Boris Alekseev, Sun-Young Rha, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 40